|Articles|February 1, 2001
- Pharmaceutical Executive-12-01-2001
- Volume 0
- Issue 0
Generics Debate Escalates
Calls for change reflect that generic products are a therapeutic mainstay and that patients and providers want earlier access to inexpensive medicines.
Advertisement
Articles in this issue
over 24 years ago
States Target DTC Advertisingover 24 years ago
Transparent Momentover 24 years ago
IFPMA Disputes Doctors Without Boarders Reportover 24 years ago
GSK at Odds with Activistsover 24 years ago
Protecting People Everywhereover 24 years ago
Opening the Door to Japanover 24 years ago
Trade Pact Weakens Patent Protectionsover 24 years ago
EC Questions Dual Pricingover 24 years ago
Genetic Test Results Off Limits-For Nowover 24 years ago
Precious PlasmaAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
2
Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio
3
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
4
Pharma Roundup: Bristol Myers Squibb Enters Strategic Agreement with Anthropic, Incyte and Genesis Expand Strategic Collaboration
5